|
Factor
|
4-year bRFS (%) (95% CI)
|
p value
|
|---|
|
Pathologic tumor stage
| |
< 0.001
|
|
T1-2
|
79.2 (66.0-92.3)
| |
|
T3-4
|
31.7 (17.0-46.4)
| |
|
Surgical margin
| |
0.652
|
|
Positive
|
48.6 (32.0-65.1)
| |
|
Negative
|
57.1 (42.7-71.4)
| |
|
Gleason score
| |
0.189
|
|
≤ 7
|
58.9 (44.5-73.3)
| |
|
≥ 8
|
35.2 (14.7-51.5)
| |
|
Preoperative PSA (ng/ml)
| |
0.037
|
|
< 10
|
62.0 (47.7-76.3)
| |
|
≥ 10
|
39.3 (22.5-56.0)
| |
|
Pre-RT PSA (ng/ml)
| |
0.620
|
|
< 0.25
|
54.5 (37.5-71.6)
| |
|
≥ 0.25
|
45.9 (30.2-64.9)
| |
|
PSA doubling time (months)
| |
0.059
|
|
< 7
|
34.6 (17.5-51.8)
| |
|
≥ 7
|
62.2 (46.7-77.7)
| |
|
RT dose (Gy)
| |
0.068
|
|
< 64
|
36.8 (15.2-58.5)
| |
|
≥ 64
|
51.7 (37.6-65.9)
| |
|
BED (Gy) (α/β = 1.5)
| |
0.213
|
|
< 145
|
41.4 (23.5-59.3)
| |
|
≥ 145
|
54.3 (39.5-69.1)
| |
|
Time from RP to RT (months)
| |
0.310
|
|
< 24
|
45.2 (29.1-61.4)
| |
|
≥ 24
|
57.4 (40.9-73.9)
| |
|
Hormone therapy
| |
0.627
|
|
Done
|
50.5 (20.2-72.9)
| |
|
Not done
|
50.7 (37.6-63.7)
| |
- Abbreviations: bRFS = biochemical relapse-free survival, RT = radiotherapy, PSA = prostate-specific antigen, BED = biological effective dose, RP = radical prostatectomy, CI = confidence interval
